New platform tests blood or saliva of early-stage lung cancer patients to identify two cancer-linked mutations, reports The Journal of Molecular Diagnostics
Non-small-cell lung carcinoma (NSCLC) is often fatal because most cases are not diagnosed until they are so advanced that surgical intervention is no longer possible. To improve outcomes researchers are developing a blood test to detect lung cancer earlier in the disease.
The steps involved in the electric field-induced capture and release (EFIRM) assay are shown. Initially, allele-specific capture probes are immobilized in a conducting polymer gel at the base of each well in a 96 well plate. Subsequently, a small amount (20 to 30 ncl) of untreated saliva or plasma is added to hybridization fluid and added directly to the well (step 1). Subsequently an alternating electric current is applied causing allele-specific hybridization. In step 2, a biotinylated signal probe is added to each well and another electrically stimulated hybridization is performed. Finally, in step 3 a standard streptavidin/biotin/horse radish peroxidase (HRP) signal amplification is performed causing electrons to be drawn up through the gold electrode and the current in nanoamperes is measured by the EFRIM reader.
Credit: Fang Wei, EZLife Bio
A report in The Journal of Molecular Diagnostics describes a new technology, electric field-induced release and measurement (EFIRM) that is both highly sensitive and specific in detecting two epidermal growth factor receptor (EGFR) mutations associated with lung cancer in the blood of NSCLC patients with early-stage disease. This platform is relatively inexpensive and capable of high-throughput testing.
Despite advances in chemotherapy, five-year survival for patients diagnosed with unresectable NSCLC is less than 10 percent. The ability to diagnose NSCLC in stages 1 and 2, when surgical resection and potential cure are still possible, could significantly reduce the mortality from NSCLC worldwide.
"The revolutionary EFIRM technology is the most exciting development in noninvasive liquid biopsy in recent years. The potential to detect early-stage lung cancer patients with an affordable blood or saliva test could save thousands to tens of thousands of lives annually worldwide," stated Charles M. Strom, MD, PhD, co-director of the Center for Oral/Head and Neck Oncology Research at the UCLA School of Dentistry, Los Angeles, CA, USA, and Senior Vice President and Chief Medical Officer of EZLife Bio, USA, Woodland Hills, CA, USA. The EFIRM technology can also be used to monitor treatment and detect recurrence in patients already diagnosed with NSCLC.
Previously, the investigators had successfully measured two actionable EGFR mutations (p.L858R and Exon 19del) in blood samples from patients with late-stage NSCLC using EFIRM technology. In the current study, they investigated whether the mutations could be found in samples from patients with early-stage disease.
The researchers collected plasma samples from 248 patients with radiographically-determined pulmonary nodules. Of those, 44 were diagnosed with Stage I or Stage II NSCLC (23 with biopsy-proven benign pulmonary nodules and 21 with Stage I or Stage II adenocarcinoma). EFIRM was able to detect the p.L858R mutation in 11 of 12 samples and the Exon 19del mutation in seven of nine samples, resulting in greater than 90 percent sensitivity and 80 percent specificity.
"Currently, the clinical sensitivity of EFIRM to detect patients with NSCLC is limited by the percentage of tumors containing either or both of the two variants, which is estimated at 27 percent of NSCLC tumors," explained co-investigator Wu-Chou Su, MD, of the Department of Internal Medicine, National Cheng Kung University Hospital and College of Medicine of the National Cheng Kung University, Tainan, Taiwan. "We are presently developing a 10-variant panel that contains detecting mutations expressed in 50 percent of all lung malignancies."
Investigators emphasize that this study does not present direct evidence that detecting EGFR mutations in the plasma of an individual is predictive that the patient has cancer. Future work will explore whether finding an EGFR mutation in the circulation has any predictive value. Currently, the EFIRM liquid biopsy may be helpful for guiding treatment selection in patients for whom biopsy material is not available.
"We are gratified by the performance of the EFIRM platform in patients whose tumors were still small enough to qualify for surgical care. Work is underway to increase the number of mutations analyzed and to automate the process to increase sensitivity and facilitate mass screening," commented Dr. Strom.
Eileen Leahy | EurekAlert!
Typical mutations in children of radar soldiers
05.10.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
Whole-brain connectome maps teach artificial intelligence to predict epilepsy outcomes
02.10.2018 | Medical University of South Carolina
Additive manufacturing processes are booming, with the rapid growth of the formnext trade fair a clear indication of this. At formnext 2018, the Fraunhofer Institute for Laser Technology ILT will be showing a new process in which the component in the powder bed is heated with laser diodes. As a result, distortion can be reduced, taller parts generated and new materials used.
In just three years, formnext has established itself as the industry meeting place to get the latest on additive manufacturing (AM) processes. With 470...
Researchers from Graz University of Technology have described for the first time the dynamics which takes place within a trillionth of a second after photoexcitation of a single atom inside a superfluid helium nanodroplet.
In his research, Markus Koch, Associate Professor at the Institute of Experimental Physics of Graz University of Technology (TU Graz), concentrates on...
Porosity is the key to high-performance materials for energy storage systems, environmental technologies or catalysts: The more porous a solid state material...
The WT1 gene fulfills a central role in the development of a healthy, proper functioning kidney. Mutations in WT1 lead to impairments in kidney development and cause Wilms tumors, a pediatric kidney cancer. Researchers of the Leibniz Institute on Aging – Fritz Lipmann Institute (FLI) in Jena have now discovered a further important function of WT1. It is also active outside the kidneys in the central nervous system and is involved in controlling movement. If the gene is missing in the spinal cord, locomotor aberrancies occur. The results have now been published in Life Science Alliance.
Transcription factor WT1 (Wilms tumor 1) has been known for nearly 30 years and it is significantly involved in the development of a healthy and properly...
A unique feature that sets neurons apart from all other cells are their beautiful, highly elaborate dendritic trees. These structures have evolved to receive the vast majority of information entering a neuron, which is integrated and processed by virtue of the dendrites’ geometry and active properties. Higher brain functions such as memory and attention all critically rely on dendritic computations, which are in turn controlled by inhibitory synaptic input. A team of scientists, led by Johannes J. Letzkus (MPI for Brain Research), now has identified a novel form of inhibition that dominantly controls dendritic function and strongly depends on previous experiences.
Our brain is a remarkably complex system. It is not only comprised of billions of neurons, but each individual neuron by itself even has exceptional processing...
02.10.2018 | Event News
01.10.2018 | Event News
21.09.2018 | Event News
08.10.2018 | Physics and Astronomy
05.10.2018 | Health and Medicine
05.10.2018 | Life Sciences